Testing whether opioids plus support change learning behavior
Treatments studied
Part of Mental health clinical trials.
This early study tests how opioid medicine, along with social support, affects how people learn or “unlearn” certain responses. If you’re healthy and meet safety requirements, it may help researchers understand how support could change the effects of pain-related medicines on behavior.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 35 years old
- Fluent in English enough to follow study instructions
- Do not have any past diagnosis of mental health conditions (like anxiety, depression, phobias, or other mental disorders)
- Do not be pregnant or planning pregnancy during the study
- Avoid being on regular prescription medicines for mental health or for liver problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study looks at how opioids affect your experience of social situations and your brain activity. It may help researchers understand how opioid medicines influence social perception and brain signaling.
This early-phase study looks at whether opioid system signals change how people feel pain and respond to feeling socially rejected, like after a breakup. It may help researchers understand why some people experience stronger pain or stress in response to rejection.
This study tests whether adding cannabidiol (CBD) to your usual methadone or buprenorphine treatment helps you recover from opioid use disorder. If you're already in stable treatment with those medications, the trial aims to see if CBD can improve your outcomes.
This trial tests whether a combination of buprenorphine (through your care plan) and a monthly extended-release naltrexone (XR-NTX) shot can help prevent opioid relapse. It may help people who are ready to move toward a naltrexone-based relapse-prevention treatment after detox.
This Phase 1 study tests how adding psilocybin to a standard opioid treatment (buprenorphine-naloxone) affects recovery and symptoms in people with moderate-to-severe opioid use disorder. It may help researchers understand whether this combination is safe and beneficial alongside medication for opioid withdrawal and cravings.
This Phase 2 study tests whether a long-acting naltrexone implant can help people with opioid use disorder stay away from opioid relapse. You may get the implant after safely finishing opioid withdrawal and stopping other naltrexone dosing at the right time.
Hear when a new Fear trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.